Latest Instructions for Use of Belzutifan

Belzutifan, a small molecule oral inhibitor targeting hypoxia-inducible factor-2α (HIF-2α), was approved by the U.S. Food and Drug Administration (FDA) in May 2025 for a new indication: the treatment of patients 12 years of age and older with locally advanced, unresectable or metastatic pheochromocytoma (pheochromocytoma) or paraganglioma (collectively referred to as PPGL). This approval is of great significance because it is the first FDA-approved oral targeted therapy for PPGL, and it also marks the further expansion of bezutifan treatment, especially a breakthrough in the management of rare tumors.

PPGL is a rare neuroendocrine tumor derived from neural crest cells and has secretory function. Patients often suffer from severe hypertension, palpitations, headaches and other symptoms due to excessive release of catecholamines by the tumor. For patients with PPGL that cannot be surgically removed or have distant metastasis, traditional treatment methods are limited, the efficacy fluctuates greatly, and the long-term tolerance is poor. Therefore, a new, highly targeted and convenient oral therapeutic drug is particularly important. Bestivan is based on a profound understanding of the key molecular mechanisms of PPGL. By inhibiting HIF-2α activity and blocking its interaction with downstream genes, it can achieve the therapeutic effect of controlling tumor progression and slowing down disease progression.

Bezotivan has shown good flexibility and safety in terms of dosage and administration methods in the new indication population. The FDA recommended usage is: adult patients take 120 mg orally once a day and continue to take the drug until disease progression or unacceptable adverse reactions occur. For pediatric patients 12 years old and above, the dose setting is more individualized and is divided into two standards based on weight. For pediatric patients weighing ≥40 kg, the daily oral dose is 120 mg, the same as for adults; while for pediatric patients weighing <40 kg, the recommended daily dose is 80 mg. All patients are advised to take their medications at the same time every day without taking them with food or avoiding certain diets. However, attention should be paid to potential interactions between medications, especially those that affect the CYP enzyme system.

The duration of drug therapy depends on the individual condition and tolerability, and is generally recommended until clear disease progression or until treatment necessitates discontinuation due to adverse events. During treatment, clinicians are recommended to closely monitor patients' hemoglobin levels, oxygen saturation, liver function and potential hypoxia-related symptoms, because besotivan inhibitionHIF-2α may affect the body's adaptability to a hypoxic environment. Especially when fatigue, dizziness, dyspnea and other symptoms occur, it should be evaluated whether it is related to the drug, and the dose should be adjusted or the drug discontinued as appropriate based on the degree of toxicity.

From a pharmacological perspective, bezotivanThe selective target makes it highly targeted at the molecular level, reducing extensive inhibition of normal tissues, thereby improving the controllability and safety of treatment. Since the HIF-2α pathway is continuously activated in many solid tumors, especially neuroendocrine tumors carrying VHL mutations or SDH defects, the mechanism of bezotivan is consistent with the pathological basis of PPGL, providing strong theoretical support and practical basis for its treatment.

In addition, the convenience of besettivan’s administration form also plays a positive role in improving patient compliance. Compared with traditional intravenous chemotherapy or radionuclide therapy, oral small molecule drugs are more suitable for long-term treatment, especially for children or patients in remote areas, helping to reduce hospitalization needs and medical costs.

References:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma